聚乙二醇干扰素α-2b的一种替代给药策略可能有助于改善骨髓增殖性肿瘤的治疗结果：既往及正在进行的研究概述与未来展望
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
作者信息
Qin Albert, Urbanski Raymond W, Yu Lennex, Ahmed Tasfia, Mascarenhas John
机构信息
PharmaEssentia Corporation, Taipei, Taiwan.
PharmaEssentia USA Corporation, Burlington, MA, United States.
出版信息
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
Abstract
Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.
摘要
聚乙二醇干扰素α-2b是一种新型的长效单聚乙二醇化脯氨酸干扰素α-2b，已被批准用于治疗成人真性红细胞增多症，无论其血栓形成风险水平或治疗史如何。临床试验数据表明，聚乙二醇干扰素α-2b的剂量和滴定是安全有效的。然而，更多研究可能为修订后的更高初始剂量和快速滴定提供依据。本文概述了聚乙二醇干扰素α-2b在骨髓增殖性肿瘤中的现有及即将开展的研究，这些研究支持探索修订后的给药方案，以优化患者耐受性和疗效结果。
相似文献
1
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.聚乙二醇干扰素α-2b的一种替代给药策略可能有助于改善骨髓增殖性肿瘤的治疗结果：既往及正在进行的研究概述与未来展望
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
2
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.罗特西普干扰素 α-2b 治疗真性红细胞增多症的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):3-7. doi: 10.1080/17425255.2021.1839050. Epub 2020 Oct 29.
3
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.一项评估罗特西普干扰素α-2b 在中国真性红细胞增多症患者中的疗效和安全性的 II 期临床试验。
Future Oncol. 2023 Apr;19(11):753-761. doi: 10.2217/fon-2022-1141. Epub 2023 May 2.
4
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.聚乙二醇干扰素α-2b用于真性红细胞增多症患者的治疗。
Drugs Today (Barc). 2020 Mar;56(3):195-202. doi: 10.1358/dot.2020.56.3.3107706.
5
Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.罗特西普那非治疗真性红细胞增多症的成本效果分析。
J Comp Eff Res. 2023 Sep;12(9):e230066. doi: 10.57264/cer-2023-0066. Epub 2023 Aug 2.
6
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好：一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.
7
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.ROP-ET 研究：一项在治疗选择有限的原发性血小板增多症患者中评估罗特西普纳治疗疗效和安全性的 III 期前瞻性研究
Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4.
8
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
9
Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.聚乙二醇干扰素α-2b治疗基因1型慢性丙型肝炎患者：药代动力学、安全性及初步疗效
JGH Open. 2021 Jul 10;5(8):929-940. doi: 10.1002/jgh3.12613. eCollection 2021 Aug.
10
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.新型长效聚乙二醇干扰素 alfa-2b：I 期临床试验中的药代动力学、药效学和安全性。
Br J Clin Pharmacol. 2022 May;88(5):2396-2407. doi: 10.1111/bcp.15176. Epub 2021 Dec 28.
引用本文的文献
1
Lipid nanoparticle-delivered IFNα2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis.脂质纳米颗粒递送的IFNα2激活Cxcl9以增加T细胞向肿瘤的募集，从而抑制肺转移。
J Immunother Cancer. 2025 Jul 31;13(7):e011415. doi: 10.1136/jitc-2024-011415.
2
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.2025年亚洲骨髓增殖性肿瘤大会亮点：骨髓增殖性肿瘤分子发病机制与治疗策略的进展
Curr Hematol Malig Rep. 2025 Jul 12;20(1):9. doi: 10.1007/s11899-025-00752-3.
3
A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.一项利用美国食品药品监督管理局不良事件报告系统（FAERS）数据库对真性红细胞增多症治疗相关不良事件进行的药物警戒研究。
Ann Hematol. 2025 Jul 10. doi: 10.1007/s00277-025-06480-1.
4
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
5
Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial.聚乙二醇干扰素α-2b与抗PD-1治疗序贯联合作为乙肝相关肝癌辅助治疗的1期剂量递增试验
Hepatol Int. 2025 Apr 5. doi: 10.1007/s12072-025-10824-4.
6
Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b.应对聚乙二醇化干扰素α-2a短缺：将患者转换为聚乙二醇化干扰素α-2b的实用指南。
Ann Hematol. 2025 Apr;104(4):2571-2573. doi: 10.1007/s00277-025-06331-z. Epub 2025 Apr 3.
7
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.PARADIGM-PV：一项随机、多中心4期研究，旨在评估聚乙二醇干扰素α-2b治疗低危或高危真性红细胞增多症患者的疗效和安全性。
Ann Hematol. 2025 Jan;104(1):335-345. doi: 10.1007/s00277-025-06185-5. Epub 2025 Jan 13.
8
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.在真性红细胞增多症患者接受聚乙二醇干扰素α-2b治疗过程中，分子学缓解与完全血液学缓解未同时出现。
Br J Haematol. 2024 Dec;205(6):2510-2514. doi: 10.1111/bjh.19846. Epub 2024 Oct 27.
9
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.一项评估罗特西普干扰素 alfa-2b 在早期/低危原发性骨髓纤维化患者中的疗效和安全性的随机、双盲、安慰剂对照 3 期研究。
Ann Hematol. 2024 Sep;103(9):3573-3583. doi: 10.1007/s00277-024-05912-8. Epub 2024 Aug 15.
10
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.一项评估聚乙二醇干扰素α-2b治疗中度新型冠状病毒肺炎（COVID-19）患者疗效和安全性的3期随机对照试验。
Infect Dis Ther. 2024 Jul;13(7):1575-1588. doi: 10.1007/s40121-024-00992-5. Epub 2024 May 21.
本文引用的文献
1
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.一项验证一种创新的长效干扰素治疗慢性丙型肝炎的效力和安全性的3期临床试验。
JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov.
2
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.骨髓增殖性肿瘤临床实践指南（第 3 版）. 2022 年 NCCN
J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046.
3
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.SURPASS-ET：聚乙二醇干扰素α-2b与阿那格雷作为原发性血小板增多症二线治疗的III期研究。
Future Oncol. 2022 Sep;18(27):2999-3009. doi: 10.2217/fon-2022-0596. Epub 2022 Aug 4.
4
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.罗特西普干扰素α-2b 在日本真性红细胞增多症患者中的疗效和安全性：一项开放标签、单臂、2 期研究。
Int J Hematol. 2022 Aug;116(2):215-227. doi: 10.1007/s12185-022-03341-9. Epub 2022 Apr 16.
5
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.真性红细胞增多症的细胞减少药物治疗的适当管理：欧洲白血病网 2021 年建议。
Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1.
6
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.新诊断真性红细胞增多症或原发性血小板增多症患者的血栓形成事件及死亡风险
Leuk Res. 2022 Apr;115:106809. doi: 10.1016/j.leukres.2022.106809. Epub 2022 Feb 16.
7
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.接受罗培戈干扰素α-2b治疗的真性红细胞增多症患者的长期预后。
Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24.
8
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.台湾地区 COVID-19 患者标签外使用罗匹尼罗干扰素 alfa-2b 的临床经验。
Adv Ther. 2022 Feb;39(2):910-922. doi: 10.1007/s12325-021-01998-y. Epub 2021 Dec 15.
9
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.新型长效聚乙二醇干扰素 alfa-2b：I 期临床试验中的药代动力学、药效学和安全性。
Br J Clin Pharmacol. 2022 May;88(5):2396-2407. doi: 10.1111/bcp.15176. Epub 2021 Dec 28.
10
Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.聚乙二醇干扰素α-2b治疗基因1型慢性丙型肝炎患者：药代动力学、安全性及初步疗效
JGH Open. 2021 Jul 10;5(8):929-940. doi: 10.1002/jgh3.12613. eCollection 2021 Aug.
Zotero 插件